BC’s Life Sciences Sector Flexes Muscle with 2026 Award Slate

VANCOUVER, BC – June 18, 2026 – Life Sciences BC (LSBC) has unveiled the recipients of its 28th Annual Awards, and the list reads like a strategic blueprint for economic dominance. The announcement celebrates a cohort of companies and individuals whose recent triumphs are not just shaping healthcare but are cementing British Columbia’s reputation as a global life sciences powerhouse. Leading the charge is Kardium, crowned Company of the Year, whose recent regulatory and commercial victories in the United States serve as a potent symbol of the sector's growing maturity and market prowess.

The annual awards, set to be presented at a gala on September 9, recognize the scientific excellence, business acumen, and leadership driving the province’s innovation ecosystem. While the ceremony offers a moment of reflection, the achievements of the winners tell a forward-looking story of a sector hitting its stride, fueled by strategic investment, a deep talent pool, and world-class research.

Kardium’s Triumph Signals MedTech Maturity

Kardium’s recognition as Company of the Year is the culmination of a transformative period for the Burnaby-based medtech firm. In September 2025, the company secured the coveted pre-market approval (PMA) from the U.S. Food and Drug Administration for its Globe Pulsed Field System, a revolutionary device for treating atrial fibrillation—an irregular heartbeat affecting millions worldwide. This was no small feat; it positioned Kardium as the fourth company to enter the highly competitive U.S. pulsed field ablation market, placing it alongside industry titans like Medtronic and Johnson & Johnson.

“We are honored to be recognized by Life Sciences BC as Company of the Year. This has been an exceptional year for Kardium, marked by FDA approval and the commercial launch of our Globe System, as well as a highly successful financing round that positions us for continued momentum,” said Kevin Chaplin, CEO, Kardium. “As we look ahead, we are excited to build on this progress—expanding our manufacturing capabilities and growing our talented team of over 700 employees right here in British Columbia.”

The FDA green light was quickly followed by a successful U.S. commercial launch in October 2025. Fueling this momentum was a staggering US$250 million Series D financing round secured in July 2025, capital earmarked for scaling manufacturing at its Vancouver facility and building out its commercial teams. For BC’s ecosystem, Kardium’s success is a powerful proof point: a local company can navigate the complex, capital-intensive journey from R&D to global commercialization, creating high-value jobs and intellectual property at home.

The Next Wave of Innovators

The LSBC awards also cast a spotlight on the next generation of disruptors. NervGen Technologies, named Emerging Company of the Year in Biotech, is advancing a potential breakthrough in neuroreparative medicine. Its lead candidate, NVG-291, is in clinical trials for treating spinal cord injury, a condition with no approved pharmacological treatments. Positive data from its Phase 1b/2a study showed statistically significant improvements in motor connectivity, offering a glimmer of hope for patients and positioning NervGen as a potential first-mover in a market with immense unmet need. The company is now preparing for a pivotal Phase 3 study, a critical step toward commercialization.

In the medtech category, Sonic Incytes earned Emerging Company of the Year for Velacur ONE™, its AI-guided ultrasound device. With FDA 510(k) clearance secured in August 2025, the portable system provides a non-invasive, real-time assessment of liver health. This innovation is critically timed to address the growing epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD). Velacur ONE™ offers a powerful point-of-care diagnostic tool that can replace costly and invasive biopsies, aligning perfectly with the healthcare system's push for efficiency and early detection.

The awards also gave a nod to a 'Companies to Watch' honour roll—including Evolved Therapeutics, Incisive Genetics, and Integrated Nanotherapeutics—signaling a deep bench of talent and innovation ready to emerge.

Honoring the Architects of an Ecosystem

Behind every successful company is a network of leaders and mentors who built the foundation for growth. The 2026 awards pay tribute to these architects. The Dr. Don Rix Lifetime Achievement Award was bestowed upon Dr. Ali Tehrani, co-founder of Zymeworks. Dr. Tehrani’s leadership was instrumental in transforming Zymeworks from a UBC spin-off into a NYSE-listed biopharmaceutical powerhouse, demonstrating that BC could anchor and scale a globally competitive biotech firm.

Brenda Irwin, recipient of the Milton Wong Community Leadership Award, was recognized for her pivotal role as a venture capitalist and mentor. As Managing Partner of the Relentless Venture Fund, she has been a crucial force in funding and guiding early-stage health-tech companies. Her work with organizations like Life Sciences BC and Creative Destruction Labs exemplifies the community-focused leadership that nurtures nascent ideas into viable enterprises.

Scientific excellence was also celebrated, with Dr. David Huntsman receiving the Scientific Entrepreneurship Award for his transformative research in ovarian cancer, which has reshaped global diagnosis and treatment standards. Dr. Joerg Bohlmann earned the Genome British Columbia Award for Scientific Excellence for his pioneering work in plant and forestry genomics, creating new avenues for pest management and high-value bioproducts.

A Strategic Blueprint for a Global Hub

The collective success of the 2026 award winners is no accident; it is the result of a deliberate, long-term strategy to build a world-class life sciences hub. The sector now supports nearly 27,000 jobs with an average salary far exceeding the provincial average, contributing over $3 billion to BC's GDP. This growth is underpinned by the provincial government's Life Sciences and Biomanufacturing Strategy, which aims to double employment over the next decade.

This strategy is visibly supported by a collaborative network of partners. The Canadian Alliance for Skills and Training in Life Sciences (CASTL), named Strategic Partner of the Year, is tackling the critical talent gap by establishing biomanufacturing training programs in the province. Key sponsors like Genome BC continue to fund foundational genomics research, while homegrown giants like AbCellera—itself a former award winner—reinvest in the ecosystem by sponsoring the awards and expanding their local footprint. This synergy between government, industry, and academia creates a resilient and self-reinforcing cycle of innovation and economic growth, proving that a security-first mindset in health can indeed become a driver of market-leading corporate strategy.